DownloadHi-Res Photo

Adam Mecca, MD, PhD

Associate Professor of Psychiatry; Associate Director, Alzheimer's Disease Research Unit; Faculty, Alzheimer's Disease Research Center (ADRC)

Research & Publications
Biography
News

Coauthors

Selected Publications

Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s diseaseYoung J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-JToyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
Hearing Loss is Associated with Faster Cognitive Decline but not Diagnostic Conversion in the ADNI CohortMiller A, Mecca A, Sharp E, van Dyck C, O'Dell R. Hearing Loss is Associated with Faster Cognitive Decline but not Diagnostic Conversion in the ADNI Cohort. American Journal Of Geriatric Psychiatry 2023, 31: e19-e20. DOI: 10.1016/j.jagp.2023.02.027.
Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PETSilva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.
Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trialsVan Dyck C, O'Dell R, Mecca A. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12388. PMID: 37187779, PMCID: PMC10175943, DOI: 10.1002/trc2.12388.
Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDGO'Dell R, Mecca A, Waszak J, Sharp E, Chen M, Naganawa M, Toyonaga T, Lu Y, Chupak A, Cooper E, Lam J, Miller A, Waldner E, Weibley H, Zhao Y, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDG. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.062595.
Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065162.
Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065064.
CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trialPandey K, Waybright L, Duong D, Malagise E, Blennow K, Zetterberg H, Mecca A, van Dyck C, Caggiano A, Seyfried N, Hamby M. CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.068166.
Investigating a CD8+ T cell age‐associated gene signature in Alzheimer's diseaseYoung J, Park H, Par‐Young J, Bartlett H, Kim H, Shin M, You S, Kim M, Allore H, Mecca A, Kang I. Investigating a CD8+ T cell age‐associated gene signature in Alzheimer's disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.064384.
P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s DiseaseKelly K, O'Dell R, Toyonaga T, Barcelos N, Gelernter J, Varma P, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease. Biological Psychiatry 2022, 91: s125-s126. DOI: 10.1016/j.biopsych.2022.02.329.
The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's diseaseKelly K, Toyonaga T, Zhao W, Barcelos N, Gelernter J, Varma P, Nabulsi N, Wyk B, Huang Y, Carson R, van Dyck C, Mecca A. The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's disease. American Journal Of Geriatric Psychiatry 2022, 30: s25. DOI: 10.1016/j.jagp.2022.01.301.
Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PETSilva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. American Journal Of Geriatric Psychiatry 2022, 30: s26. DOI: 10.1016/j.jagp.2022.01.303.
All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent BiomarkersO'Dell R, van Dyck C, Mecca A. All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent Biomarkers. American Journal Of Geriatric Psychiatry 2022, 30: s24. DOI: 10.1016/j.jagp.2022.01.295.
Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Zhao W, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C, Nilsson J. Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054831.
Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐Jvan Dyck C, Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054213.
Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory PerformanceDatta D, Leslie SN, Woo E, Amancharla N, Elmansy A, Lepe M, Mecca AP, Slusher BS, Nairn AC, Arnsten AFT. Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory Performance. Frontiers In Aging Neuroscience 2021, 13: 760270. PMID: 34867287, PMCID: PMC8634091, DOI: 10.3389/fnagi.2021.760270.
Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial NetworkZhou B, Wang R, Chen M, Mecca A, O’Dell R, Van Dyck C, Carson R, Duncan J, Liu C. Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. 2021, 12906: 34-43. DOI: 10.1007/978-3-030-87231-1_4.
Generation of synthetic PET images of synaptic density and amyloid from 18F‐FDG images using deep learningWang R, Liu H, Toyonaga T, Shi L, Wu J, Onofrey JA, Tsai Y, Naganawa M, Ma T, Liu Y, Chen M, Mecca AP, O’Dell R, van Dyck C, Carson RE, Liu C. Generation of synthetic PET images of synaptic density and amyloid from 18F‐FDG images using deep learning. Medical Physics 2021, 48: 5115-5129. PMID: 34224153, PMCID: PMC8455448, DOI: 10.1002/mp.15073.
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's diseaseLu Y, Toyonaga T, Naganawa M, Gallezot JD, Chen MK, Mecca AP, van Dyck CH, Carson RE. Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease. NeuroImage 2021, 238: 118248. PMID: 34119639, PMCID: PMC8454285, DOI: 10.1016/j.neuroimage.2021.118248.
Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PETMecca AP, Rogers K, Jacobs Z, McDonald JW, Michalak HR, DellaGioia N, Zhao W, Hillmer AT, Nabulsi N, Lim K, Ropchan J, Huang Y, Matuskey D, Esterlis I, Carson RE, van Dyck CH. Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET. NeuroImage 2021, 238: 118217. PMID: 34052464, PMCID: PMC8378132, DOI: 10.1016/j.neuroimage.2021.118217.
Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysisFang XT, Toyonaga T, Hillmer AT, Matuskey D, Holmes SE, Radhakrishnan R, Mecca AP, van Dyck CH, D’Souza D, Esterlis I, Worhunsky PD, Carson RE. Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. NeuroImage 2021, 237: 118167. PMID: 34000404, PMCID: PMC8452380, DOI: 10.1016/j.neuroimage.2021.118167.
Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-JO'Dell R, Mecca A, Sharp E, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Carson R, Arnsten A, van Dyck C. Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J. Biological Psychiatry 2021, 89: s107-s108. DOI: 10.1016/j.biopsych.2021.02.276.
Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression.Pathak GA, Wendt FR, Levey DF, Mecca AP, van Dyck CH, Gelernter J, Polimanti R. Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression. Human Molecular Genetics 2021, 30: 1360-1370. PMID: 33831179, PMCID: PMC8255129, DOI: 10.1093/hmg/ddab102.
Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-JO'Dell R, Mecca A, Chen M, Naganawa M, Toyonaga T, Lu Y, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Nabulsi N, Ropchan J, Ye Y, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C. Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s37-s40. DOI: 10.1016/j.jagp.2021.01.034.
Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-JSharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A, van Dyck C. Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s119-s120. DOI: 10.1016/j.jagp.2021.01.114.
Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Banks E, Bartlett H, Harris J, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal Of Geriatric Psychiatry 2021, 29: s47-s48. DOI: 10.1016/j.jagp.2021.01.041.
Recipes for Adult Learning: Innovations in teaching neuroimaging to geriatric traineesFahed M, Lane C, Khasnavis S, Mecca A. Recipes for Adult Learning: Innovations in teaching neuroimaging to geriatric trainees. American Journal Of Geriatric Psychiatry 2021, 29: s16-s17. DOI: 10.1016/j.jagp.2021.02.022.
Molecular Imaging in Alzheimer's Disease: Linking pathologic, neurotransmitter, synaptic and clinical findings relevant to geriatric psychiatryDonovan N, Mecca A, Smith G, Gatchel J. Molecular Imaging in Alzheimer's Disease: Linking pathologic, neurotransmitter, synaptic and clinical findings relevant to geriatric psychiatry. American Journal Of Geriatric Psychiatry 2021, 29: s8. DOI: 10.1016/j.jagp.2021.02.004.
Developing Your Reseach CareerGatchel J, Mecca A, Padala P. Developing Your Reseach Career. American Journal Of Geriatric Psychiatry 2021, 29: s13-s14. DOI: 10.1016/j.jagp.2021.02.016.
Amyloid-Associated Depression—or Not?van Dyck CH, O'Dell RS, Mecca AP. Amyloid-Associated Depression—or Not? Biological Psychiatry 2021, 89: 737-738. PMID: 33766236, PMCID: PMC8396710, DOI: 10.1016/j.biopsych.2021.02.008.
Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling studyChen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O’Dell R, McDonald JW, Michalak HR, Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study. Cerebrovascular And Brain Metabolism Reviews 2021, 41: 2395-2409. PMID: 33757318, PMCID: PMC8393289, DOI: 10.1177/0271678x211004312.
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-JO’Dell R, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Nabulsi NB, Ropchan J, Ye Y, Vander Wyk BC, Huang Y, Arnsten AFT, Carson RE, van Dyck CH. Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research & Therapy 2021, 13: 11. PMID: 33402201, PMCID: PMC7786921, DOI: 10.1186/s13195-020-00742-y.
ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s diseaseFang X, Mecca A, Naganawa M, O'Dell R, Chen M, van Dyck C, Carson R. ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041197.
In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s diseaseMecca A, O'Dell R, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Zhao W, Gallezot J, Nabulsi N, Ropchan J, Ye Y, Wyk B, Arnsten A, Huang Y, Carson R, van Dyck C. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037791.
Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PETO'Dell R, Naganawa M, Toyonaga T, Young J, Dahal R, Singh E, Waheed A, Banks E, Harris J, Chen M, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PET. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.045928.
PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037792.
Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Harris J, Bartlett H, Banks E, Kominek V, Nabulsi N, Najafzadeh S, Wyk B, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044211.
11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043584.
Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET studyO'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Ropchan J, Ye Y, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043631.
Alzheimer's & Dementia: The Journal of the Alzheimer's AssociationMecca AP, van Dyck C. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Alzheimer's & Dementia 2020, 17: 316-317. PMID: 33047474, PMCID: PMC7962853, DOI: 10.1002/alz.12190.
Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human CohortNaganawa M, Gallezot JD, Finnema SJ, Matuskey D, Mecca A, Nabulsi NB, Labaree D, Ropchan J, Malison RT, D'Souza DC, Esterlis I, Detyniecki K, van Dyck CH, Huang Y, Carson RE. Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort. Journal Of Nuclear Medicine 2020, 62: 418-421. PMID: 32646875, PMCID: PMC8049341, DOI: 10.2967/jnumed.120.243949.
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETMecca AP, Chen M, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck C. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's & Dementia 2020, 16: 974-982. PMID: 32400950, PMCID: PMC7383876, DOI: 10.1002/alz.12097.
Amyloid: From Starch to FinishKrystal HL, Ross DA, Mecca AP. Amyloid: From Starch to Finish. Biological Psychiatry 2020, 87: e23-e24. PMID: 32299582, PMCID: PMC7449531, DOI: 10.1016/j.biopsych.2020.02.1182.
Session 401Fahed M, Lane C, Khasnavis S, Mecca A. Session 401. American Journal Of Geriatric Psychiatry 2020, 28: s38-s39. DOI: 10.1016/j.jagp.2020.01.070.
Session 102Donovan N, Mecca A, Smith G, Gatchel J. Session 102. American Journal Of Geriatric Psychiatry 2020, 28: s4. DOI: 10.1016/j.jagp.2020.01.017.
ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDYO'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal Of Geriatric Psychiatry 2020, 28: s123-s124. DOI: 10.1016/j.jagp.2020.01.153.
PET imaging of mGluR5 in Alzheimer’s diseaseMecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. PET imaging of mGluR5 in Alzheimer’s disease. Alzheimer's Research & Therapy 2020, 12: 15. PMID: 31954399, PMCID: PMC6969979, DOI: 10.1186/s13195-020-0582-0.
Statin Use and Risk of Cognitive Decline in the ADNI CohortKemp EC, Ebner MK, Ramanan S, Godek TA, Pugh EA, Bartlett HH, McDonald JW, Mecca MC, van Dyck CH, Mecca AP, Initiative T. Statin Use and Risk of Cognitive Decline in the ADNI Cohort. American Journal Of Geriatric Psychiatry 2019, 28: 507-517. PMID: 31806426, PMCID: PMC7170771, DOI: 10.1016/j.jagp.2019.11.003.
P4‐481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCEMecca A, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Gallezot J, Charil A, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. P4‐481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's & Dementia 2019, 15: p1497-p1497. DOI: 10.1016/j.jalz.2019.08.027.
IC‐P‐140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASEMecca A, Chen M, Godek T, Harris J, Bartlett H, Toyonaga T, Naganawa M, Salardini A, Arnsten A, Nabulsi N, Lim K, Najafzadeh S, Ropchan J, Huang Y, Carson R, Strittmatter S, van Dyck C. IC‐P‐140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2019, 15: p115-p115. DOI: 10.1016/j.jalz.2019.06.4254.
P2‐349: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY OF HEALTHY AGING AND ALZHEIMER'S DISEASEMecca A, Chen M, Godek T, Harris J, Bartlett H, Toyonaga T, Naganawa M, Salardini A, Arnsten A, Nabulsi N, Lim K, Najafzadeh S, Ropchan J, Huang Y, Carson R, Strittmatter S, van Dyck C. P2‐349: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY OF HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2019, 15: p729-p729. DOI: 10.1016/j.jalz.2019.06.2756.
Development and Validation of a Polypharmacy Knowledge Assessment InstrumentThomas JM, Mecca MC, Niehoff KM, Mecca AP, Van Ness PH, Brienza R, Hyson A, Jeffery S. Development and Validation of a Polypharmacy Knowledge Assessment Instrument. American Journal Of Pharmaceutical Education 2019, 83: 6435. PMID: 31333246, PMCID: PMC6630871, DOI: 10.5688/ajpe6435.
1ciii AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systemsMecca AP. 1ciii AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems. 2019, 165: 139-165. PMID: 31481161, DOI: 10.1016/bs.pmbts.2019.04.003.
Assessing an Interprofessional Polypharmacy and Deprescribing Educational Intervention for Primary Care Post-graduate Trainees: a Quantitative and Qualitative EvaluationMecca MC, Thomas JM, Niehoff KM, Hyson A, Jeffery SM, Sellinger J, Mecca AP, Van Ness PH, Fried TR, Brienza R. Assessing an Interprofessional Polypharmacy and Deprescribing Educational Intervention for Primary Care Post-graduate Trainees: a Quantitative and Qualitative Evaluation. Journal Of General Internal Medicine 2019, 34: 1220-1227. PMID: 30972554, PMCID: PMC6614292, DOI: 10.1007/s11606-019-04932-9.
ADVANCES IN THE MOLECULAR IMAGING OF ALZHEIMER'S DISEASE: NEUROBIOLOGICAL MECHANISMS OF DISEASE AND NEUROPSYCHIATRIC SYMPTOMS Session 209Mecca A, Smith G, Gatchel J, Donovan J. ADVANCES IN THE MOLECULAR IMAGING OF ALZHEIMER'S DISEASE: NEUROBIOLOGICAL MECHANISMS OF DISEASE AND NEUROPSYCHIATRIC SYMPTOMS Session 209. American Journal Of Geriatric Psychiatry 2019, 27: s17-s18. DOI: 10.1016/j.jagp.2019.01.158.
ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASEGupta M, O'Dell R, Gelernter J, Carson R, van Dyck C, Mecca A. ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s143-s144. DOI: 10.1016/j.jagp.2019.01.098.
REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASEO'Dell R, Gupta M, Gelernter J, Carson R, van Dyck C, Mecca A. REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. American Journal Of Geriatric Psychiatry 2019, 27: s145-s146. DOI: 10.1016/j.jagp.2019.01.100.
Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic ImagingChen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology 2018, 75: 1215-1224. PMID: 30014145, PMCID: PMC6233853, DOI: 10.1001/jamaneurol.2018.1836.
Effects of Normative Adjustments to the Montreal Cognitive AssessmentPugh EA, Kemp EC, van Dyck CH, Mecca AP, Sharp ES, Initiative F. Effects of Normative Adjustments to the Montreal Cognitive Assessment. American Journal Of Geriatric Psychiatry 2018, 26: 1258-1267. PMID: 30314940, PMCID: PMC6779033, DOI: 10.1016/j.jagp.2018.09.009.
IC‐04‐03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASEMecca A, McDonald J, Michalak H, Godek T, Harris J, Chen M, Nabulsi N, Salardini A, Carson R, Strittmatter S, van Dyck C. IC‐04‐03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2018, 14: p8-p9. DOI: 10.1016/j.jalz.2018.06.2051.
P1‐469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASEMecca A, McDonald J, Michalak H, Godek T, Harris J, Chen M, Nabulsi N, Salardini A, Carson R, Strittmatter S, van Dyck C. P1‐469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2018, 14: p501-p503. DOI: 10.1016/j.jalz.2018.06.479.
P2‐365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCEChen M, Mecca A, Naganawa M, Finnema S, Toyonaga T, Gallezot J, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. P2‐365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's & Dementia 2018, 14: p832-p832. DOI: 10.1016/j.jalz.2018.06.1056.
IC‐P‐183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCEMecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, Gallezot J, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. IC‐P‐183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's & Dementia 2018, 14: p152-p153. DOI: 10.1016/j.jalz.2018.06.2250.
Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI CohortMecca AP, Michalak HR, McDonald JW, Kemp EC, Pugh EA, Becker ML, Mecca MC, van Dyck CH. Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort. Dementia And Geriatric Cognitive Disorders 2018, 45: 232-242. PMID: 29886490, PMCID: PMC6178799, DOI: 10.1159/000488671.
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trialBarcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.
Delays in the Air or Ground Transfer of Patients for Endovascular ThrombectomyRegenhardt RW, Mecca AP, Flavin SA, Boulouis G, Lauer A, Zachrison KS, Boomhower J, Patel AB, Hirsch JA, Schwamm LH, Leslie-Mazwi TM. Delays in the Air or Ground Transfer of Patients for Endovascular Thrombectomy. Stroke 2018, 49: 1419-1425. PMID: 29712881, PMCID: PMC5970980, DOI: 10.1161/strokeaha.118.020618.
Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?Mecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? American Journal Of Geriatric Psychiatry 2018, 26: s145-s146. DOI: 10.1016/j.jagp.2018.01.176.
Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's diseaseMecca AP, Barcelos NM, Wang S, Brück A, Nabulsi N, Planeta-Wilson B, Nadelmann J, Benincasa AL, Ropchan J, Huang Y, Gelernter J, Van Ness PH, Carson RE, van Dyck CH. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease. Neurobiology Of Aging 2017, 61: 207-214. PMID: 29111487, PMCID: PMC5722236, DOI: 10.1016/j.neurobiolaging.2017.09.027.
Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PETMecca A, Rogers K, Jacobs Z, McDonald J, Michalak H, DellaGioia N, Nabulsi N, Matuskey D, Esterlis I, Carson R, van Dyck C. Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET. American Journal Of Geriatric Psychiatry 2017, 25: s96-s97. DOI: 10.1016/j.jagp.2017.01.110.
Poster Number: EI 40 Characteristics of Older Adults with Homelessness or Housing InstabilityHassell C, Mecca M, Mecca A. Poster Number: EI 40 Characteristics of Older Adults with Homelessness or Housing Instability. American Journal Of Geriatric Psychiatry 2017, 25: s97-s99. DOI: 10.1016/j.jagp.2017.01.119.
Poster Number: EI 11 Screening PRogram to Identify Needs Due to Geriatric Syndromes (SPRING): A New Perspective on Healthcare for Homeless AdultsDeWorsop D, Mecca M, Maiaroto M, Rodriguez-Guzman J, Hassell C, Mecca A, Iheanacho T. Poster Number: EI 11 Screening PRogram to Identify Needs Due to Geriatric Syndromes (SPRING): A New Perspective on Healthcare for Homeless Adults. American Journal Of Geriatric Psychiatry 2016, 24: s77-s79. DOI: 10.1016/j.jagp.2016.01.076.
Poster Number: EI 51 Characterizing Trajectories of Homelessness in Older AdultsHassell C, Mecca M, DeWorsop D, Rodriguez-Guzman J, Maiaroto M, Iheanacho T, Mecca A. Poster Number: EI 51 Characterizing Trajectories of Homelessness in Older Adults. American Journal Of Geriatric Psychiatry 2016, 24: s116-s118. DOI: 10.1016/j.jagp.2016.01.116.
Poster Number: EI 10 Utilizing a Direct Assessment to Identify Functional Impairments in Homeless AdultsRodriguez-Guzman J, Maiaroto M, DeWorsop D, Hassell C, Iheanacho T, Mecca A, Mecca M. Poster Number: EI 10 Utilizing a Direct Assessment to Identify Functional Impairments in Homeless Adults. American Journal Of Geriatric Psychiatry 2016, 24: s76-s77. DOI: 10.1016/j.jagp.2016.01.075.
P3‐143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's diseasevan Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. P3‐143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p680-p681. DOI: 10.1016/j.jalz.2015.06.1011.
IC‐P‐101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's diseasevan Dyck C, Mecca A, Wang S, Barcelos N, Planeta-Wilson B, Gelernter J, Van Ness P, Carson R. IC‐P‐101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first‐degree relatives at varying ApoE4 risk for Alzheimer's disease. Alzheimer's & Dementia 2015, 11: p69-p69. DOI: 10.1016/j.jalz.2015.06.123.
Chapter 28 Mas and Neuroprotection in StrokeBennion D, Regenhardt R, Mecca A, Sumners C. Chapter 28 Mas and Neuroprotection in Stroke. 2015, 201-205. DOI: 10.1016/b978-0-12-801364-9.00028-6.
Idiom Use in a Young Man with Schizophrenia and Prominent Sexual DelusionsFineberg SK, Mecca A, Lerner BA, Hills OF, Corlett PR, Viron M. Idiom Use in a Young Man with Schizophrenia and Prominent Sexual Delusions. Harvard Review Of Psychiatry 2014, 22: 306-315. PMID: 25188734, DOI: 10.1097/hrp.0000000000000053.
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic strokeJoseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, Patel NA, Pioquinto DJ, Unger T, Katovich MJ, Steckelings UM, Sumners C. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014, 81: 134-141. PMID: 24508710, PMCID: PMC7472595, DOI: 10.1016/j.neuropharm.2014.01.044.
Centrally administered angiotensin‐(1–7) increases the survival of stroke‐prone spontaneously hypertensive ratsRegenhardt RW, Mecca AP, Desland F, Ritucci‐Chinni P, Ludin JA, Greenstein D, Banuelos C, Bizon JL, Reinhard MK, Sumners C. Centrally administered angiotensin‐(1–7) increases the survival of stroke‐prone spontaneously hypertensive rats. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2013, 99: 442-453. PMID: 24142453, PMCID: PMC7416533, DOI: 10.1113/expphysiol.2013.075242.
Anti-inflammatory effects of angiotensin-(1-7) in ischemic strokeRegenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, Sumners C. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013, 71: 154-163. PMID: 23583926, PMCID: PMC3664115, DOI: 10.1016/j.neuropharm.2013.03.025.
Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery OcclusionRegenhardt R, Ansari S, Azari H, Caldwell K, Mecca A. Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion. Journal Of Visualized Experiments 2013 DOI: 10.3791/50015-v.
Utilizing a cranial window to visualize the middle cerebral artery during endothelin-1 induced middle cerebral artery occlusion.Regenhardt RW, Ansari S, Azari H, Caldwell KJ, Mecca AP. Utilizing a cranial window to visualize the middle cerebral artery during endothelin-1 induced middle cerebral artery occlusion. Journal Of Visualized Experiments 2013, e50015. PMID: 23463164, PMCID: PMC3605805, DOI: 10.3791/50015.
Endothelin-1 Induced Middle Cerebral Artery Occlusion Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in RatAnsari S, Azari H, Caldwell K, Regenhardt R, Hedna V, Waters M, Hoh B, Mecca A. Endothelin-1 Induced Middle Cerebral Artery Occlusion Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in Rat. Journal Of Visualized Experiments 2013 DOI: 10.3791/50014-v.
Endothelin-1 induced middle cerebral artery occlusion model for ischemic stroke with laser Doppler flowmetry guidance in rat.Ansari S, Azari H, Caldwell KJ, Regenhardt RW, Hedna VS, Waters MF, Hoh BL, Mecca AP. Endothelin-1 induced middle cerebral artery occlusion model for ischemic stroke with laser Doppler flowmetry guidance in rat. Journal Of Visualized Experiments 2013 PMID: 23438950, PMCID: PMC3601209, DOI: 10.3791/50014.
Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic strokeMecca AP, Regenhardt RW, O’Connor T, Joseph JP, Raizada MK, Katovich MJ, Sumners C. Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2011, 96: 1084-1096. PMID: 21685445, PMCID: PMC3210510, DOI: 10.1113/expphysiol.2011.058578.
Angiotensin(1–7) increases survival of stroke‐prone spontaneously hypertensive ratsRegenhardt R, Ritucci‐Chinni P, Desland F, Mecca A, Sumners C. Angiotensin(1–7) increases survival of stroke‐prone spontaneously hypertensive rats. The FASEB Journal 2011, 25: 650.10-650.10. DOI: 10.1096/fasebj.25.1_supplement.650.10.
Central and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic StrokeJoseph J, Regenhardt R, Mecca A, Patel N, Steckelings U, Unger T, Katovich M, Sumners C. Central and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic Stroke. The FASEB Journal 2011, 25: lb576-lb576. DOI: 10.1096/fasebj.25.1_supplement.lb576.
Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizuresCao W, Glushakov A, Shah HP, Mecca AP, Sumners C, Shi P, Seubert CN, Martynyuk AE. Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizures. Amino Acids 2010, 40: 1151-1158. PMID: 20839013, PMCID: PMC8396070, DOI: 10.1007/s00726-010-0739-4.
Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular DiseasesFerreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular Diseases. Hypertension 2009, 55: 207-213. PMID: 20038757, PMCID: PMC2826213, DOI: 10.1161/hypertensionaha.109.140145.
Efficacy of 3,5‐dibromo‐L‐phenylalanine in rat models of stroke, seizures and sensorimotor gating deficitCao W, Shah H, Glushakov A, Mecca A, Shi P, Sumners C, Seubert C, Martynyuk A. Efficacy of 3,5‐dibromo‐L‐phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit. British Journal Of Pharmacology 2009, 158: 2005-2013. PMID: 20050189, PMCID: PMC2807662, DOI: 10.1111/j.1476-5381.2009.00498.x.
FP19-TU-03 3,5-Dibromo-l-phenylalanine depresses pentylenetetrazole-induced seizures and reduces neurological and sensorimotor gating deficits caused by strokeMartynyuk A, Sumners C, Cao W, Shah H, Mecca A, Seubert C. FP19-TU-03 3,5-Dibromo-l-phenylalanine depresses pentylenetetrazole-induced seizures and reduces neurological and sensorimotor gating deficits caused by stroke. Journal Of The Neurological Sciences 2009, 285: s87. DOI: 10.1016/s0022-510x(09)70364-8.
Candesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusionMecca AP, O'Connor TE, Katovich MJ, Sumners C. Candesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusion. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2009, 94: 937-946. PMID: 19429641, PMCID: PMC2742297, DOI: 10.1113/expphysiol.2009.047936.
Cerebroprotective action of angiotensin 1‐7 in a rat model of ischemic strokeMecca A, O'Connor T, Dooies K, Katovich M, Sumners C. Cerebroprotective action of angiotensin 1‐7 in a rat model of ischemic stroke. The FASEB Journal 2009, 23: 947.1-947.1. DOI: 10.1096/fasebj.23.1_supplement.947.1.
Paraventricular nucleus (PVN) neurons projecting to the rostral ventrolateral medulla (RVLM) contain both oxytocin and glutamateShi P, Jiang N, Li H, Mecca A, Raizada M, Sumners C. Paraventricular nucleus (PVN) neurons projecting to the rostral ventrolateral medulla (RVLM) contain both oxytocin and glutamate. The FASEB Journal 2009, 23: 967.6-967.6. DOI: 10.1096/fasebj.23.1_supplement.967.6.
Overexpression of Angiotensin II type 2 receptor (AT2R) in neonatal cardiomyocytes induces apoptosisQi Y, Li H, Mecca A, Shenoy V, Sumners C, Katovich M. Overexpression of Angiotensin II type 2 receptor (AT2R) in neonatal cardiomyocytes induces apoptosis. The FASEB Journal 2008, 22: 1238.18-1238.18. DOI: 10.1096/fasebj.22.1_supplement.1238.18.
Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertensionGrobe J, Mecca A, Lingis M, Shenoy V, Bolton T, Machado J, Speth R, Raizada M, Katovich M. Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertension. The FASEB Journal 2007, 21: a896-a897. DOI: 10.1096/fasebj.21.6.a896-d.
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). AJP Heart And Circulatory Physiology 2006, 292: h736-h742. PMID: 17098828, DOI: 10.1152/ajpheart.00937.2006.
Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in ratsMitra A, Katovich MJ, Mecca A, Rowland NE. Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. Physiology & Behavior 2006, 89: 221-225. PMID: 16839572, DOI: 10.1016/j.physbeh.2006.06.006.
Angiotensin 1‐7 prevents cardiac fibrosis in angiotensin II and DOCA‐salt models of hypertensionGrobe J, Mecca A, Lingis M, Mao H, Katovich M. Angiotensin 1‐7 prevents cardiac fibrosis in angiotensin II and DOCA‐salt models of hypertension. The FASEB Journal 2006, 20: a305-a306. DOI: 10.1096/fasebj.20.4.a305-d.
Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertensionGrobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. AJP Heart And Circulatory Physiology 2006, 290: h2417-h2423. PMID: 16415071, DOI: 10.1152/ajpheart.01170.2005.
Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in ratsHuentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2005, 90: 783-790. PMID: 16049057, DOI: 10.1113/expphysiol.2005.031096.

Clinical Trials

Conditions	Study Title
Alzheimer's Disease	AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Aging; Mental Health & Behavioral Research	A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Mental Health & Behavioral Research	Imaging mGluR5 and synaptic density in psychiatric disorders
Mental Health & Behavioral Research	Studying the Adult Brain
Alzheimer's Disease	A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease (ENVISION)

Edit Profile

Adam Mecca, MD, PhD

Contact Information

Patient Care

Research & Publications

Biography

News

Coauthors

Selected Publications

Clinical Trials